Luc Cournoyer

Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA.

Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA.

DFINE, Inc.engages in the development and commercialization of medical device system for treating vertebral compression fractures. The company was founded by John H. Shadduck and Csaba Truckai in 2004 and is headquartered in South Jordan, UT.

Auxillium Energy, Inc. is an exploration stage company. It engages in the investigation, acquisition, exploration and development of oil and gas properties in Alaska. The company was founded on November 9, 2009 and is headquartered in White Plains, NY.

Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ.

Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA.

Emphasys Medical, Inc., a medical technology company, focuses on developing and commercializing minimally invasive therapeutic devices for the treatment of patients with emphysema and other breathing disorders. It offers Zephyr Endobronchial Valve system, which is designed to block air from passing through the opening in the lung and into the chest cavity, resulting in the reduction or elimination of airflow through the leak to allow the tissue to heal. The company offers its products through distributors and dealers in Europe, Australia, Hong Kong, and Singapore. Emphasys Medical was founded in 2000 and is based in Redwood City, CA. Emphasys Medical, Inc. operates as a subsidiary of Pulmonx Corp.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Cerapedics, Inc. engaged in the provision of developing and commercializing novel osteobiologic products. It offers i-FACTOR Bone Graft, an advanced biologic that supported with level I evidence, and provides benefit ratio. The company was founded by Andrew J. Tofe and is headquartered in Westminster, CO.

LifeCell Corp. develops and markets tissue repair products. The firm focuses on reconstructive, urogynecologic and orthopedic surgical procedures. Its products include alloderm, strattice, graft jacket, allocraftdbm and repliform. The company was founded in 1986 and is headquartered in Branchburg, NJ.

Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA.

Orthovita, Inc. engages in the development and commercialization of synthetic biologically-active tissue engineering products for restoration of the human skeleton. The company was incorporated in 1992 and is headquartered in Malvern, PA.

Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY.